The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
February 5th 2025
Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).
How HepC Care Provided by Pharmacists Differs From Other Care Settings
July 28th 2016Jennifer Andres, PharmD, BCPS, clinical assistant professor of pharmacy practice at Temple University Schools of pharmacy describes how hepatitis C care in the pharmacy differs from care provided in other settings.
Watch